CONTESTABILE A. The history of the cholinergic hypothesis[J]. Behav Brain Res,2011, 221(2):334-340.
[2]
KARRAN E, MERCKEN M, DE STROOPER B. The amyloid cascade hypothesis for Alzheimer''s disease: an appraisal for the development of therapeutics[J]. Nat Rev Drug Discov,2011, 10(9):698-712.
[3]
SVENSSON AL, ALAFUZOFF I, NORDBERG A. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists[J]. Brain Res,1992, 596(1-2):142-148.
[4]
BODICK NC, OFFEN WW, LEVEY AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease[J]. Arch Neurol,1997, 54(4):465-473.
ODDO S, CACCAMO A, SHEPHERD JD, et al. Triple-transgenic model of Alzheimer''s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction[J]. Neuron,2003, 39(3):409-421.
[7]
CHEN CD, PODVIN S, GILLESPIE E, et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17[J]. Proc Natl Acad Sci U S A,2007, 104(50):19796-19801.
[8]
FU H, DOU J, LI W, et al. Promising multifunctional anti-Alzheimer''s dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently[J]. Eur J Pharmacol,2009, 623(1-3):14-21.
[9]
CAILLE I, ALLINQUANT B, DUPONT E, et al. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone[J]. Development,2004, 131(9):2173-2181.
[10]
GAKHAR-KOPPOLE N, HUNDESHAGEN P, MANDL C, et al. Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway[J]. Eur J Neurosci,2008, 28(5):871-882.
[11]
FREUDE KK, PENJWINI M, DAVIS JL, et al. Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells[J]. J Biol Chem,2011, 286(27):24264-24274.
[12]
CACCAMO A, FISHER A, LAFERLA FM. M1 agonists as a potential disease-modifying therapy for Alzheimer''s disease[J]. Curr Alzheimer Res,2009, 6(2):112-117.
[13]
ECKOLS K, BYMASTER FP, MITCH CH, et al. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells[J]. Life Sci,1995, 57(12):1183-1190.
[14]
DELAPP N, WU S, BELAGAJE R, et al. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells[J]. Biochem Biophys Res Commun,1998, 244(1):156-160.
[15]
BYMASTER FP, CARTER PA, PETERS SC, et al. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects[J]. Brain Res,1998, 795(1-2):179-190.
[16]
WOOD MD, MURKITT KL, HO M, et al. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry[J]. Br J Pharmacol,1999, 126(7):1620-1624.
[17]
SAMS AG, HENTZER M, MIKKELSEN GK, et al. Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-p henylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential[J]. J Med Chem,2010, 53(17):6386-6397.
[18]
VEROFF AE, BODICK NC, OFFEN WW, et al. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB)[J]. Alzheimer Dis Assoc Disord,1998, 12(4):304-312.
[19]
CHASSEIGNEAUX S, ALLINQUANT B. Functions of Abeta, sAPPalpha and sAPPbeta : similarities and differences[J]. J Neurochem,2012, 120 Suppl 1:99-108.
[20]
WEI J, WALTON EA, MILICI A, et al. m1-m5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC[J]. J Neurochem,1994, 63(3):815-821.
[21]
CACCAMO A, ODDO S, BILLINGS LM, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice[J]. Neuron,2006, 49(5):671-682.
[22]
FISHER A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer''s disease[J]. J Neurochem,2012, 120 Suppl 1:22-33.
[23]
TAYLOR CJ, IRELAND DR, BALLAGH I, et al. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory[J]. Neurobiol Dis,2008, 31(2):250-260.
[24]
DAVIS AA, FRITZ JJ, WESS J, et al. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo[J]. J Neurosci,2010, 30(12):4190-4196.
